Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 21, 2012, Pages 8298-8303

  Biagini, Giancarlo A ^a   Fisher, Nicholas ^a   Shone, Alison E ^a   Mubaraki, Murad A ^a   Srivastava, Abhishek ^a   Hill, Alisdair ^a   Antoine, Thomas ^a   Warman, Ashley J ^a   Davies, Jill ^a   Pidathala, Chandrakala ^b   Amewu, Richard K ^b   Leung, Suet C ^b   Sharma, Raman ^b   Gibbons, Peter ^b   Hong, David W ^b   Pacorel, Bénédicte ^b   Lawrenson, Alexandre S ^b   Charoensutthivarakul, Sitthivut ^b   Taylor, Lee ^b   Berger, Olivier ^b   Mbekeani, Alison ^a   Stocks, Paul A ^a   Nixon, Gemma L ^a   Chadwick, James ^b   Hemingway, Janet ^a   Delves, Michael J ^c   Sinden, Robert E ^c   Zeeman, Anne Marie ^d   Kocken, Clemens H M ^d   Berry, Neil G ^b   O'Neill, Paul M ^b   Ward, Stephen A ^a   more..

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; CHLOROQUINE; CK 2 68; PROTOZOAL PROTEIN; PYRIMIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SL 2 25; SL 2 64; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; ENZYME SPECIFICITY; IC 50; MALARIA; MALARIA CONTROL; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PARASITE CLEARANCE; PLASMODIUM BERGHEI INFECTION; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PYRIMIDINE METABOLISM;

ANIMALS; ANTIMALARIALS; CELLS, CULTURED; ELECTRON TRANSPORT; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX III; HEPATOCYTES; MACACA MULATTA; MALARIA, FALCIPARUM; MALE; MICE; MICE, INBRED STRAINS; MITOCHONDRIA; PLASMODIUM BERGHEI; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PYRIDINES; QUINOLONES;

PLASMODIUM BERGHEI; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM;

EID: 84861429203     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205651109     Document Type: Article

References (28)

1. Fry M, Pudney M (1992) Site of action of the antimalarial hydroxynaphthoquinone, 2- [trans-4-(4′-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43:1545-1553.
2. Srivastava IK, Rottenberg H, Vaidya AB (1997) Atovaquone, a broad spectrum anti-parasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 272:3961-3966. (Pubitemid 27078454)
3. Hammond DJ, Burchell JR, Pudney M (1985) Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3- hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol 14:97-109. (Pubitemid 15171433)
4. Painter HJ, Morrisey JM, Mather MW, Vaidya AB (2007) Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446:88-91. (Pubitemid 46348043)
5. Fisher N, Bray PG, Ward SA, Biagini GA (2007) The malaria parasite type II NADH: quinone oxidoreductase: An alternative enzyme for an alternative lifestyle. Trends Parasitol 23:305-310. (Pubitemid 46935569)
6. Hopkins AL (2008) Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 4:682-690.
7. Fisher N, Warman AJ, Ward SA, Biagini GA (2009) Chapter 17 Type II NADH: Quinone oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and high-throughput assays. Methods Enzymol 456:303-320.
8. Durant JL, Leland BA, Henry DR, Nourse JG (2002) Reoptimization of MDL keys for use in drug discovery. J Chem Inf Comput Sci 42:1273-1280. (Pubitemid 35468313)
9. Willett P (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11:1046-1053.
10. Geppert H, Vogt M, Bajorath J (2010) Current trends in ligand-based virtual screening: Molecular representations, data mining methods, new application areas, and performance evaluation. J Chem Inf Model 50:205-216.
11. Liu K, Feng J, Young SS (2005) Power MV: A software environment for molecular viewing, descriptor generation, data analysis and hit evaluation. J Chem Inf Model 45:515-522. (Pubitemid 40635359)
12. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249.
13. Yeates CL, et al. (2008) Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J Med Chem 51:2845-2852. (Pubitemid 351620805)
14. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
15. Biagini GA, Viriyavejakul P, O'neill PM, Bray PG, Ward SA (2006) Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob Agents Chemother 50:1841-1851.
16. Biagini GA, et al. (2008) Acridinediones: Selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol Pharmacol 73:1347-1355. (Pubitemid 351574824)
17. Seymour KK, Yeo AE, Rieckmann KH, Christopherson RI (1997) dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. Ann Trop Med Parasitol 91:603-609. (Pubitemid 27434594)
18. Dembele L, et al. (2011) Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS ONE 6:e18162.
19. Peters W, Robinson BL (1999) Malaria (Academic, San Diego).
20. Barton V, Fisher N, Biagini GA, Ward SA, O'Neill PM (2010) Inhibiting Plasmodium cytochrome bc1: A complex issue. Curr Opin Chem Biol 14:440-446.
21. Bray PG, Mungthin M, Ridley RG, Ward SA (1998) Access to hematin: The basis of chloroquine resistance. Mol Pharmacol 54:170-179. (Pubitemid 28337600)
22. Suswam E, Kyle D, Lang-Unnasch N (2001) Plasmodium falciparum: The effects of atovaquone resistance on respiration. Exp Parasitol 98:180-187. (Pubitemid 32912749)
23. Trager W, Jensen JB (1976) Human malaria parasites in continuous culture. Science 193:673-675.
24. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M (2004) Simple and in-expensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48:1803-1806. (Pubitemid 38544392)
25. Delves M, et al. (2012) The activities of current antimalarial drugs on the life cycle stages of Plasmodium: A comparative study with human and rodent parasites. PLoS Med 9:e1001169.
26. Solmaz SR, Hunte C (2008) Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer. J Biol Chem 283:17542-17549.
27. Rabinowitz JD, Kimball E (2007) Acidic acetonitrile for cellular metabolome extraction from Escherichia coli. Anal Chem 79:6167-6173. (Pubitemid 47282327)
28. O'Neill PM, et al. (2009) Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J Med Chem 52:1408-1415.